The present secondary analysis study ( 1 ) examined the relationship between maternal buprenorphine dose at delivery and neonatal abstinence syndrome ( NAS ) peak score , estimated gestational age at delivery , Apgar scores at 1 and 5 min , neonatal head circumference , length , and weight at birth , amount of morphine needed to treat NAS , duration of NAS treatment , and duration of neonatal hospital stay and ( 2 ) compared neonates who required pharmacotherapy for NAS to neonates who did not require such pharmacotherapy on these same outcomes , in 58 opioid-dependent pregnant women receiving buprenorphine as participants in a randomized clinical trial .